PPT-PEG alfa-2a RBV versus

PEG alfa 2a versus INF RBV APRICOT STUDY Phase 3 Treatment Naïve Chronic HCV and HIV Torriani FJ et al N Engl J Med 200435143850 PEG RBV versus PEG . ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR + SMV placebo + PEG-IFN + RBV. Randomisation*. 1 : 1. Double-blind. ≥ 18 years. HCV genotype 1. HCV RNA ≥ 10,000 IU. /ml. Null or partial responders to . John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. Regional Pharmacy Director, NY/NJ AETC. Pharmacist, Albany Medical Center. Objectives. Discuss recent guidelines . changes for HIV infection. Using . patient cases, discuss the role of . Mark S. Sulkowski, MD. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/Hepatology. Johns Hopkins University School of Medicine. Baltimore, Maryland. Treatment-Naive Data . HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAILAND. When to Treat HCV. . HCV Direct-Acting . Antivirals. (. DAAs. ) in . development. . OVERVIEW. Know your epidemic: what matters. Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IFN + RBV. Randomisation. Open-label. 18-65 years. HCV genotype 1. HCV RNA > 10,000 IU/ml. Naïve (MALACHITE-I). Failure to . prior PEG-IFN + RBV. (MALACHITE-II). RBV . versus. . PEG alfa-. 2a . versus. INF + RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . + . RBV . versus. . Interferon alfa-2b + Ribavirin . Phase 3. Treatment. . Naïve, Chronic HCV. Manns. . MP, et. al. Lancet. 2001;358:958-65. Peginterferon alfa-2b + Ribavirin . versus . Interferon alfa-2b + Ribavirin . Pegasys. ). Prepared by: David Spach, MD & H. Nina Kim, MD. Last Updated: February . 14, . 2014. Background and Dosing. Peginterferon alfa-2a (. Pegasys. ). Peginterferon alfa-2a (. Pegasys. ). Summary. Phase 3. Treatment. . Naïve, Chronic HCV. McHutchison. . JG, et al. N . Engl. J Med. 1998;339:1485-92.. I. nterferon . alfa-. 2b . +/- Ribavirin for Chronic HCV. Study . Outline. Study. -. . Randomized, double-blinded, placebo controlled, phase 3 trial. Overview. . of. . PECS . projects. European Space . Agency Information . Day. 1. 1. th. January. , 2017. Point of Contact: . Ms. . Maite. Trujillo: maite.trujillo@esa.int. Mr. Laurent . Marchand. Randomisation. Open-label. W8. * Liver biopsy or . Fibroscan. . > 12.5 . kPa. or . Fibrotest. . . >. 0.75 + APRI . > 2. Objective. Primary endpoint: SVR. 12 . (HCV RNA < 15 IU/mL), full analysis set . Editorial April 2018 Alfa Laval reserves the right to change specifications without prior notification. Smooth - running ballast water treatment with Alfa Laval PureBallast 3 Dowa Line, USA, Case s . Interferon . alfa-2a. Phase 3. Treatment. . Naïve, Chronic HCV. Zeuzem. S, et al. N . Engl. J Med. 2000;343:1666-72.. Source: . Zeuzem. S, . et al. . N Engl J Med. 2000;343:1666-72.. Peginterferon alfa-2a versus Interferon alfa-. Como ser un Hombre Alfa PDF GRATIS - DESCARGAR LIBRO de Hombres Peligrosos™ » Los secretos para seducir que los chicos alfa no quieren que sepas